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Proapoptotic drugs targeting themitochondrial Bcl-2 rheostat of apoptosis are tools to selectively kill cancer
cells. Sato et al. (2011) expand the available toolkit by identifying the target of the cytotoxic natural product
aurilide in the prohibitin Opa1-dependent apoptotic cristae remodeling.Programmed cell death and its morpho-
logic manifestation of apoptosis is
a conserved pathway that, in its basic
tenets, appears operative in all meta-
zoans. During embryonic development,
cell death is essential for successful
organogenesis and the crafting of
complex multicellular tissues (Wasilewski
and Scorrano, 2009). Apoptosis also op-
erates in adult organisms to maintain
normal cellular homeostasis, and resis-
tance to apoptosis is a hallmark of cancer,
often contributing to chemoresistance.
Several key apoptotic pathways are
altered in cancer, including the loss of
function mutations in the p53 tumor
suppressor gene, as well as the overex-
pression of antiapoptotic proteins such
as the mitochondrial antioncogenes
Bcl-2 andBcl-XL (Hanahan andWeinberg,
2000). Mitochondria are key organelles in
apoptosis, since they amplify prodeath
stimuli by releasing into the cytoplasm
cytochrome c and other protein cofactors
that are required for the activation of the
caspases that execute the demise of the
cell. The permeabilization of mitochondria
during apoptosis is controlled by
members of the Bcl-2 family and is
accompanied bymorphological and ultra-
structural changes (the so-called ‘‘cristae
remodeling’’) that allow the complete
release of cytochrome c (Wasilewski and
Scorrano, 2009). Defective apoptosis
allows cancer cells to extend their life-
span, to acquire further genetic muta-
tions, to grow under unfavorable
conditions, and even to support tumor
angiogenesis. Since survival of cancer
cells depends on these changes in
apoptosis, novel ‘‘selective’’ anticancer
drugs are being produced that could, in
principle, spare normal cells that are less8 Chemistry & Biology 18, January 28, 2011 ªdependent on these alterations (Hanahan
and Weinberg, 2000). For example,
several drugs that target the Bcl-2
proteins are already in clinical trials
(Zhang et al., 2007). In this issue, Sato
et al. (2011) extend the molecular path-
ways targeted by proapoptotic drugs to
the ultrastructural changes occurring to
mitochondria during apoptosis.
Aurilide is a small cyclodepsipeptide
derived from Dolabella auricularia that
exerts potent cytotoxic effect. This mole-
cule induces apoptosis in human cancer
cells at low concentrations (Suenaga
et al., 2008), but its molecular targets
were unknown. Sato et al. (2011) demon-
strate that aurilide selectively binds to
prohibitin (Phb) 1, thereby identifying for
the first time a molecule that induces
apoptosis through the pathway of mito-
chondrial cristae remodeling controlled
by Phb and by the dynamin-like GTPase
optic atrophy 1 (Opa1). Affinity matrix
chromatography followed by mass spec-
trometry of the identified peptides re-
vealed Phb1 as a unique aurilide-binding
protein, whereas its homolog Phb2 had
no detectable affinity for the biomolecule.
Phb1 and Phb2 are ubiquitously ex-
pressed membrane proteins that are
highly conserved throughout eukaryotes.
They are involved in several cell pro-
cesses and they play a crucial role in
sustaining cancer cell proliferation and
adhesion (Sievers et al., 2010). Phb1 and
Phb2 form large assemblies in the inner
mitochondrial membrane where they
regulate the processing of Opa1 (Merk-
wirth et al., 2008). Opa1 has genetically
distinguishable functions in mitochondrial
fusion and in apoptosis by regulating the
process of cristae remodeling. Remodel-
ing of the mitochondrial cristae is required2011 Elsevier Ltd All rights reservedto mobilize the bulk of cytochrome c from
the cristae space to the intermembrane
space, where it can be released across
the outer mitochondrial membrane. En-
forced expression of Opa1 blocks cristae
remodeling and delays apoptosis, sub-
stantiating a role for cristae remodeling
in the control of cell death (Frezza et al.,
2006).
Genetic deletion of Phb results in aber-
rant cristae morphogenesis, impaired cell
proliferation, and increased apoptosis,
dependent on the increased proteolytic
processing of Opa1 (Merkwirth et al.,
2008). Phb1 interacts with spastic para-
plegia 7 (SPG7), a component of human
m-AAA protease complex involved in
Opa1 processing (Wasilewski and Scor-
rano, 2009). Aurilide treatment resulted
in Phb1-SPG7 complex disruption, sug-
gesting that aurilide could interfere with
normal Opa1 processing. Furthermore,
aurilide accumulated in mitochondria
and induced fragmentation of the organ-
elle, similar to what is observed in cells
lacking Phb. Accordingly, aurilide accel-
erated the processing of Opa1, resulting
in a greater conversion of long into short
isoforms. However, this does not confirm
that the killing mechanism depends on
Phb and Opa1. This was elegantly tested
by Sato et al. (2011) by Phb1 silencing
and overexpression experiments that
confirmed that aurilide depended on the
Phb complex. Finally, cells expressing
amutant of Opa1 that is resistant to prote-
olysis were protected from aurilide,
further substantiating how stability of
Opa1 is important for the mechanism by
which this molecule induced cell death.
Indeed, a high molecular weight oligomer
composed of both short and long forms of
Opa1 determines the resistance of
Figure 1. Molecular Mechanisms of Action of Proapoptotic Mitochondrial Drugs: BH3
Mimetics and Aurilide
While BH3 mimetics lead to outer membrane permeabilization by acting on the Bcl-2 rheostat, aurilide
shows a newmechanism by acting on the Phb/Opa1-dependent cristae remodeling pathway. Key molec-
ular players are defined in the legend. OM, outer membrane; IBM, inner boundary membrane; CJ, cristae
junction; IMS-Opa1, soluble Opa1; IM-Opa1, membrane integral Opa1.
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Aurilide is in this respect the first molecule
shown to specifically activate the Opa1-
dependent branch of apoptosis by selec-
tively inhibiting Phb1, ultimately leading to
the processing of Opa1, the destabiliza-
tion of its oligomers, and the enhanced
release of cytochrome c. It is still unclear
how the disruption of normal Opa1 func-
tion can lead to permeabilization of the
outer membrane. In this respect, it is
conceivable that aurilide has additional
mitochondrial targets that result in the
activation of the multidomain proapop-
totics, or that destabilization of cristae
structure is somehow transmitted to the
outer membrane. Future work will eluci-
date the fine mechanism, and analogs ofaurilide with lower mitochondria-permea-
bilizing effects might be of considerable
value in combined chemotherapy with
Bcl-2 inhibitors, for example.
The work of Sato et al. (2011) opens
new avenues in the quest for targeted
proapoptotic molecules that act at the
mitochondrial level and offers a proof of
the principle that mitochondrial shape
changes can be targeted to induce
apoptosis in cancer cells, as they have
been exploited to conversely reduce
damage in neurodegenerative (Costa
et al., 2010) and ischemic diseases
(Wang et al., 2010). In this respect, it is
interesting that in earlier studies aurilide
has been reported to be exquisitely active
against cells derived from prostate cancerChemistry & Biology 18, January 28, 20and leukemias (Han et al., 2006), suggest-
ing an exploration of whether levels of Phb
or Opa1 are upregulated in these specific
cancers.
In conclusion, this elegant work repre-
sents the successful identification of a
drug that induces apoptosis by interfering
with the normal mechanisms that govern
the morphogenesis of mitochondria, and
by destabilizing the cristae-shaping
protein Opa1 (Figure 1). Future work will
definitely increase the molecular toolkit
that activates mitochondrial apoptosis
from the inner membrane.REFERENCES
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